Curis FY26 Q1 net loss widens to $24.2 million; revenue logs no revenue

• Curis posted a net loss of $24.2 million, or $1.25 per share, for quarter ended March 31, 2026, widening from a $10.6 million loss a year earlier.
• Revenue was absent following sale of Erivedge royalties in fourth-quarter 2025, versus $2.4 million a year earlier.
• Research and development expense fell to $6.4 million from $8.5 million, while general and administrative costs rose to $5.1 million from $4 million.
• Other expense climbed to $12.7 million from $0.5 million on a change in fair value of warrant liability tied to January 2026 PIPE financing.
• Cash and cash equivalents totaled $15 million; runway forecast extends into second-half 2027, including up to $20.2 million of potential Series B warrant proceeds tied to dosing fifth patient in TakeAim CLL study expected later in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curis Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605121600PR_NEWS_USPR_____NE57821) on May 12, 2026, and is solely responsible for the information contained therein.